Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.64 |
| ▸ | CA2 | P00918 | 12/20 | 0.64 |
| ▸ | CA12 | O43570 | 9/20 | 0.64 |
| ▸ | CA9 | Q16790 | 9/20 | 0.64 |
| ▸ | CA4 | P22748 | 6/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12408330 | 0.82 | CA1 (0.61) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2279105 | 0.79 | CA1 (0.64) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2284057 | 0.79 | CA1 (0.67) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2287321 | 0.79 | CA1 (0.67) | CA1CA2CA12CA9CA4 | |
| SCHEMBL20788644 | 0.78 | CA1 (0.76) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2281044 | 0.78 | CA1 (0.78) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2281417 | 0.78 | CA1 (0.82) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2279116 | 0.78 | CA1 (0.65) | CA1CA2CA12CA9CA4 | |
| SCHEMBL594922 | 0.77 | CA1 (0.74) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2279765 | 0.76 | CA1 (0.62) | CA1CA2CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493489-B2 | Boron-containing small molecules as anti-protozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20110207702-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207702-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2010045503-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207702-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENTS | BRDT, BRI3BP, BTN3A1 | CA1 1800/4885CA2 194/4885CA12 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.